Boehringer Ingelheim's CEO dismisses rare earths, yet the company's pharmaceutical supply chain dependency on China runs deep and fragile. (read full article...)
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.